Study title: BL 103836,GCGD4-002 - Long-term safety and efficacy of Actimmune therapy in children with chronic granulomatous disease (CGD): Summary of data from the National Institutes of Health cohort in children initiating Actimmune prior to 1 year of age and prior to 3 years of age, respectively.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Immune System Diseases [C20] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: INTERFERON GAMMA (1B) | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: GCGD4-002 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | Y | Y | - | |